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ABSTRACT 
 
Evaluation of Immune Response and Performance in Steers of Known Genetic 
Background Vaccinated and Challenged with Bovine Viral Diarrhea Virus. 
 (December 2010) 
Chase Anthony Runyan, B.S., Oklahoma State University 
Chair of Advisory Committee: Dr. Andy D. Herring 
 
This research was directed at investigating the variation in immune response of 
cattle when administered a known challenge from Bovine Viral Diarrhea Virus (BVDV) 
following different Bovine Respiratory Disease (BRD) vaccine treatments.  Cattle were 
assigned vaccine treatments with sire and cow family was stratified across treatments to 
assess the role genetic differences may impact immune function.  The same BVDV 
strain and challenge technique were used in two trials (2008 and 2009) in Angus-sired 
yearling steers.  Data from these two years were analyzed separately because the cattle 
were managed and fed differently. 
Blood antibody Immunoglobulin-G (IgG) titers for IBR, BVD Type 1 and BVD 
Type 2 were higher for cattle in the Killed vaccine group than the MLV or NON 
vaccinated groups (P < 0.05) in both years.  In the 2008 study, average daily gain (ADG) 
was higher for cattle from the Killed vaccine group (P < 0.05) for the 28 d following 
BVDV challenge, but no cattle were classified as morbid based on rectal temperature.  In 
the 2009 study, differences in rectal temperatures were observed, and a total of 35 of 93 
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having over 40.0oC (28 in the first 14 d following challenge).  Cattle in the MLV vaccine 
group had lower overall mean temperatures, with no animals having rectal temperatures 
over 40oC 14 d following viral challenges.  Differences in rectal temperature were also 
observed due to sire.  Differences in feed intake also occurred due to treatment, day, 
treatment × day interaction, and maternal-grandsire.  The MLV vaccine group 
maintained more constant levels of intake as compared to Killed and NON vaccinated 
cattle at days 5 to 12.  Although large differences in titers following BVDV challenge 
were observed, the relationships of this immune response with animal health and 
performance appears very complex.   
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CHAPTER I 
INTRODUCTION 
Bovine Respiratory Disease (BRD) is costly to U.S. beef production due to 
effects on weight gain, production efficiency, antibiotic therapy, and in some cases 
animal death.  In spite of improved efforts for prevention and treatment, there is also 
evidence that morbidity manifests as sub-clinical illness and can result in irritations of 
the lungs and, in severe cases, pulmonary tissue damage in animals never identified for 
illness.  Breed differences pertaining to BRD occurrences have been reported, but the 
genetic influences of BRD still remain largely unknown.   There are also questions that 
remain about immune responses and protection offered by killed vs. modified-live BRD 
vaccines.  Bovine Viral Diarrhea (BVD) is a disease that is a component of BRD and is a 
threat to cattle production systems not only from its threat of morbidity and mortality 
from transient infection, but also the incidence of cattle persistently infected with the 
virus.  As a result, the objectives of this project were to: (1) evaluate genetic variation 
and vaccination effects on immune response and health measures in steers of known 
background that were challenged with Bovine Viral Diarrhea Virus (BVDV) following 
killed, modified-live or no BRD vaccination, (2) evaluate genetic and vaccination effects 
on weight gain and other traditional performance measures following vaccination and 
BVDV challenge, and (3) investigate potential genetic-vaccine treatment interactions for 
immune, health and performance measures.   
 
This thesis follows the style of the Journal of Animal Science.  
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CHAPTER II 
   LITERATURE REVIEW 
Animal health can be summarized as the overall physical condition and well 
being of animals.  In beef cattle, morbidity (sickness) accounts for reductions in 
performance and creates additional costs associated with treatment mortality (death 
loss), which can result in huge economic losses.  Morbidity and mortality in growing 
cattle on pasture and in feedlots can be the result of numerous disorders, most commonly 
respiratory and digestive associated diseases (Smith, 1998). 
It is well understood that Bovine Respiratory Disease (BRD) is an enormous 
burden in beef cattle operations.  In terms of financial strain on the U.S. cattle industry, 
Griffin (1997) summarized an estimated annual loss of $750 million due to BRD 
incidence.  Chirase and Greene (2001) reported a similar range of estimated loss of $800 
to $900 million annually from death loss occurrence, reduced feed intake resulting in 
reduced gain performance, and treatment associated costs.  McNeill et al. (1996) 
summarized Texas A&M Ranch to Rail data and concluded that a difference of $93 
added expense per animal can be attributed to cattle treated for BRD versus cattle that 
have not been treated.    
These financial strains reflect the concern over the incidence of morbidity due to 
BRD.  Galyean et al. (1999) calculated that 52% of U.S. feedlot morbidity was a result 
of BRD.  Snowder et al. (2006) reported incidence of BRD as high as 43.8% in 18,112 
cattle over a 15-year period from herds at the U.S. Meat Animal Research Center at Clay 
Center, NE.  Edwards (1996) reported morbidity of up to 82% as the result of BRD and 
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summarized that morbidity and mortality from BRD was most common in the first 45 
days after arrival at the feedlot.  Cattle are at a higher risk early in the feeding period 
when viral and bacterial exposure is compounded with high stress during arrival periods.  
Pre-exposed cattle from various geographic locations, breed types, immune status, and 
management systems are comingled in the feed yard shortly before arrival through 
regional auctions (Edwards, 2010). Efforts to reduce the amount of stress incurred 
during the receiving period is important especially for those cattle who are deemed as 
higher risk than others.  Metaphylactic programs and prevention methods deserve 
attention when dealing with more susceptible, high risk cattle (Duff and Galyean, 2007).     
Occurrences of BRD are the result of pathogenic bacteria and the presence of one 
or more viral infections (Daniels et al., 2000).  The viral agents that contribute to BRD 
are Bovine Herpes Virus-1 (BHV-1), Parainfluenza-3 virus (PI-3), Bovine Respiratory 
Syncytial Virus (BRSV) and Bovine Viral Diarrhea Virus (BVDV).  These viruses create 
suppressed immune response activity which facilitates bacterial pneumonia caused by 
Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma 
spp.  (Fulton et al. 2000; Fulton et al. 2002; Fulton et al. 2006). 
Incidence and morbidity of BRD has been recorded between breeds, although it 
has not been heavily researched.  Muggli-Cockett et al. (1992) reported Pinzqauer 
offspring had a higher incidence frequency for BRD postweaning at 24.6% as compared 
to the lowest incidence frequency of 11.8% for the Angus in herds from the Germ Plasm 
Utilization project where 10,142 cattle were evaluated from 1983 to 1988.  Snowder et 
al. (2006) also evaluated MARC herd BRD data from 1987 to 2001, and observed 
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incidence frequency for BRD was highest for Pinzqauer, Braunvieh, Simmental, and 
Limousin at 35%, 34%, 33%, and 32%, respectively.  The Angus breed was the lowest at 
10.2%, and the overall mean was 12.8% in the 12 breeds represented.  Snowder et al. 
(2005) also reported MARC III composite (¼ Angus, ¼ Hereford, ¼ Pinzguaer, ¼ Red 
Poll) as not only having a lower incidence frequency of BRD at 9.7%, but also one of the 
highest mortality rates at 17.2%. They concluded that some breeds or breed 
combinations are inherently more sensitive to BRD than others. 
Signs of clinical illness from BRD often include fever, depression and reduced 
appetite.  Buhman et al. (2000) recorded lower frequency and duration of feed intake 
behavior in newly arrived feedlot cattle that were identified as sick vs. non-sick. Sick 
steers were identified using a scoring system that included a rectal temperature of greater 
the 40.0°C, visual signs of changes in attitude, cough, nasal secretion, ocular secretion, 
and hematologic examinations.  A reduction in weight gain was reported by Gardner et 
al. (1999) as they observed 1.47 kg/d for treated cattle and 1.53kg/day for untreated 
cattle using visual symptoms and rectal temperature greater than 40°C.  Roeber et al. 
(2001) also observed similar response in cattle treated more than once having .25 kg/d 
reduction in average daily gain (ADG) as compared to cattle not being treated based on 
visual diagnosis of morbidity.  Schneider et al. (2009) reported cattle that were treated 
for BRD or had presence of lung lesions had a 0.07 kg/d reduction in ADG as compared 
to non treated cattle with no lung lesions. 
There appears to be disconnecting evidence in the literature for ADG response 
and BRD incidence, however.  Wittum et al. (1996) found no difference in ADG 
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between treated and untreated cattle, but did conclude that 68% of untreated steers 
displayed pulmonary lesions at slaughter.  Further investigation by Wittum et al. (1996) 
in the same study concluded that steers exhibiting lung lesions, regardless of treatment 
status, did have a 0.076 kg/d reduction in ADG as compared to cattle exhibiting no signs 
of lung lesions upon harvest.   
Traditionally, illness in cattle has been identified by changes in behavior that 
differ from healthy cattle.  Trained animal handling personnel, experienced in pointing 
out these changes, use signs of depression, increased rectal temperature, lethargy, nasal 
and ocular secretion, gauntness, or coughing as signs of clinical illness; followed by 
therapy or treatments that are applied accordingly.  Even still, a gap exists between 
observations and evidence of infection.  Wittum et al. (1996) observed that 78% of cattle 
treated for BRD had pulmonary lesions evident at slaughter, whereas 68% of untreated 
steers also displayed pulmonary lesions at slaughter as compared to cattle with no 
pulmonary lesions.  Gardner et al. (1999) also observed the presence of lung lesion in 
37% of non-treated cattle.  Similar observations were made by Schneider et al. (2009) 
where 60.6% of cattle never treated had lung abrasions present, and 74% of cattle that 
were treated also displayed lung tissue damage.  These observations reflect the ability of 
infection to arise unnoticed by accepted clinical symptoms, however these subclinical 
infections are also harmful in terms of additional health stress which results in lost 
performance.  
 The focus of this thesis is the impact of Bovine Viral Diarrhea Virus (BVDV) on 
immune response and performance, so it is discussed in more detail than the other viral 
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components and pathogens of BRD.  The greatest threat of BVDV comes primarily from 
persistently infected (PI) cattle.  PI calves result from vertical transmission of BVDV 
from the infected dam’s bloodstream to her fetus during pregnancy (Larson et al., 2002).  
BVDV hinders beef cattle production on a substantial economic scale as the estimated 
cost of a single occurrence of PI in a beef herd has been estimated to range from $14.85 
to $24.84 per cow annually (Larson et al., 2002).  It is important to note that the 
occurrence of PI calves in-utero happens between day 45 and day 175 of pregnancy 
(Grooms, 2004) during the time when the calf immune system is developing.  
Persistently infected calves fail to create an immune response to the BVD virus because 
they do not distinguish the virus from itself, and serve as reservoirs of infection for other 
cattle (Chase et al., 2008).  Because a failure to respond to the infection has occurred, PI 
cattle continuously shed BVD virus through horizontal transmission from one animal to 
the other through mucosal secretions (Larson et al., 2002).  
Bovine Viral Diarrhea virus can be classified into 2 genotypes (BVD type 1 and 
BVD type 2).  Beyond these distinctions, each type has several subtypes such as BVD1a, 
BVD1b, BVD1c, etc; BVD1b is the most prevailing subtype in U.S. feedlots, whereas 
BVD1d is the most common in Australia (Fulton et al., 2003b; Fulton et al., 2009). 
Beyond these genotype separations, there is also a difference in biotypes for BVD.  The 
biotype is defined as cytopathic or non-cytopathic (Ahn et al., 2005; Peterhans et al., 
2003).  These biotypes are classified based on the presence or absence of visible 
cytopathic, degenerative or degrading, effects in infected BVDV cell cultures.  Ahn et al. 
(2005) recorded differences in occurrence of biotypes for BVDV as 30% of samples 
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were defined as cytopathic (CP) and 70% were non-cytopathic (NCP).  Fulton et al. 
(2000) reported similar figures in vaccinated and non vaccinated steers with 20.8% of 
collected samples were CP, and 79.2% of samples were NCP. 
Clinical symptoms of BVDV as reviewed by Peterhans et al. (2003) and Fulton 
et al. (2003a) include those similar to other respiratory infections.  Further, the virus can 
affect the digestive tract, fetal development, and the immune system in addition to 
causing mucosal disease.  BVDV has a dual nature for infection; BVDV itself serves as 
an infectious agent, but it also serves as an immunosuppressor of health defenses (Baker, 
1995).  With defense mechanisms suppressed, secondary bacterial colonization can 
occur which commonly leads to subsidiary infections (Edwards et al., 1986). 
In terms of handling the occurrences of BVD, an important aspect is accurate 
screening and diagnosis of Persistently Infected (PI) calves.  Sandvik (2005) described in 
detail numerous methods of laboratory testing for BVD virus itself through virus 
isolations, or immune function response to BVD, or via virus neutralizing antibodies.  
Cornish et al. (2005) summarized important characteristics of laboratory testing for 
detecting PI calves to have large capacity, be economical, accurate, and timely in order 
to be suitable for practical application. 
Immunity is the ability to resist disease or infection from foreign substance that 
threatens homeostasis and wellbeing, and the complexity of the immune system is very 
extent.  Two major components of immune function exist.  The innate system, which is a 
non-specific response mechanism, and the adaptive immune system, which is antigen 
specific and leads to immunological memory (Abbas and Lichtman, 2007).  The 
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principal components of innate immunity are (1) physical and chemical barriers, such as 
epithelia and antimicrobial substances produced at epithelial surfaces; (2) phagocytic 
cells (neutrophils, macrophages) and natural killer (NK) cells; (3) blood proteins, 
including members of the complement system and other mediators of inflammation; and 
(4) cytokine proteins that regulate and coordinate many of the activities of the cells of 
innate immunity. 
The mechanisms of innate immunity are specific for structures that are common 
to groups of related microbes and may not distinguish fine differences between foreign 
substances.  Innate immunity provides the early lines of defense against microbes 
(Abbas and Lichtman, 2007).  Conversely, the adaptive immune system has an 
extraordinary capacity to distinguish among different, even closely related microbes and 
molecules, and for this reason is also called specific immunity (Abbas and Lichtman, 
2007).    
There are two types of adaptive immune responses; humoral immunity and cell-
mediated immunity.  Cell-mediated is derived by different components of the immune 
system and function to eliminate different types of microbes.  Humoral immunity is 
mediated by antibodies in the blood and mucosal secretions and produced by B 
lymphocytes (also known as B cells).  Cell-mediated immunity, also called cellular 
immunity, is mediated by T lymphocytes (also known as T cells).  Intracellular 
microbes, such as viruses and some bacteria, survive and proliferate inside phagocytes 
and other host cells, where they are inaccessible to circulating antibodies.  Defense 
against such infections is a function of cell-mediated immunity, which promotes the 
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destruction of microbes residing in phagocytes or the killing of infected cells to 
eliminate reservoirs of infection (Abbas and Lichtman, 2007). 
Protective immunity against a microbe may be induced by the host’s response to 
the microbe or by the transfer of antibodies or lymphocytes specific for the microbe.  
The form of immunity that is induced by exposure to a foreign antigen is called active 
immunity because the immunized individual plays an active role in responding to the 
antigen (Abbas and Lichtman, 2007). 
Immunity can also be conferred on an individual by transferring serum or 
lymphocytes from a specifically immunized individual.  The recipient of such a transfer 
becomes immune to the particular antigen without ever having been exposed to or 
having responded to that antigen.  Therefore, this form of immunity is called passive 
immunity (Abbas and Lichtman, 2007), and is the primary mechanism by which cows 
provide immunity to their calves through colostrums. 
 Vaccine products generally contain modified-live (MLV) or killed viruses and 
bacteria toxins known to cause diseases.  These products are administered to initiate the 
body’s immune system into creating antibodies and develop immunological memory 
(Faries, 1999).  Adjuvants are also included in available vaccines to slow the release of 
the antigen into the system to extend the immune response.  Historically, most killed 
vaccine adjuvents are comprised of aluminum hydroxide or oil and water combinations, 
(Roth and Hednerson, 2001).  Vaccines can contain an assortment biological agents, 
inactive toxins known as toxoids, killed bacteria known as bacterins and combinations of 
adjuvents which elevate the level of effectiveness of the antigens (Faries, 1999).   
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Faries (1999) also summarized that vaccines are identified as either infectious or 
noninfectious vaccines.  Infectious vaccines contain an organism that is modified or 
altered to reduce its virulence so that it will not cause disease, but will still be infectious 
enough to provide immunity.  MLV vaccines are infectious vaccines that achieve a 
desired level of infection.  Immunity of the animal prevents the establishment of disease 
and provides immunity.  Noninfectious vaccines are unable to infect or replicate 
infectious agents.  Generally, noninfectious vaccines are weaker in their ability to illicit 
an immune response, so a second dose, or booster, is required 2-4 weeks later.  The 
initial dose of vaccine is a priming, sensitizing dose that provides little to no protection 
and the booster provides protection for 6 to 12 months (Faries, 1999). 
 There appears to be some variance among reported studies pertaining to the 
duration of protection that vaccines provide.  Cortese et al. (1998) concluded that 
vaccination with a MLV BVD Type 1 triggered antibodies to numerous strains of both, 
BVD type 1 and BVD type 2 that were detectable 18 months post vaccination.  Reports 
from Fulton et al. (1995) indicate a decline in BVD antibody titers by day 140 following 
vaccination. 
 Some vaccines, which target specific antigens, such as toxoid vaccines, are 
meant to completely prevent disease from infection, whereas vaccines which are 
formulated for more complex agents of disease that tend to have more numerous 
antigenic strains are less likely to achieve a complete prevention level of protection 
(Faries, 1999).  Callan and Garry (2002) summarized respiratory vaccines as disease 
modifiers rather than absolute preventative agents. 
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 Additional benefits of vaccinatation exist which not only protects vaccinated 
individuals, but also reduces the ability to shed infections to pen mates or newly arrived  
comingled calves (Frank et al., 2003).  Vaccinations are an important feature in reducing 
the spread of diseases, but practices that prevent pathogen introduction, limit exposure, 
and reduce transmission are all important steps upon entry into the feedlot (Snowder et 
al., 2006).     
  Viruses use two different strategies to infect hosts.  Peterhans (2003) reviewed 
that a virus may either cause a persistent infection in individual animals to infect new 
hosts, or, viruses can also use the ‘hit-and-run” strategy which is a short duration 
followed by a rapid transfer to a different host and continuing. 
Virulence of BVDV has been characterized as having a broad range of effects 
based upon the amount of infection or severity of infection induced (Ridpath and Neill,  
2007).  Liebler-Tenorio et al. (2003) observed differences in clinical observations and 
rectal temperature changes in colostrum deprived, non-vaccinated steers less than 4 
months of age when challenged with 2 different BVDV type 2 strains.  Observations 
were made following an intranasal challenge of a naturally occurring low virulent strain, 
or a highly virulent strain isolated from a severe field outbreak.  Calves receiving the 
low virulent strain expressed a mildly elevated body temperature at day 7 following 
challenge with no changes in feed intake or observable behavior differences.  
Conversely, calves inoculated with the highly virulent strain exhibited elevated body 
temperature (>40oC) shortly following challenge which persisted for several days.  
Calves in the high virulence group also became lethargic and apathetic in behavior.  
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Similar findings were made by Kelling et al. (2002) where 5 different isolates of BVDV 
type II (2 highly virulent strains and 2 lowly virulent strains) were experimentally 
induced into 6 to 9 month old crossbred calves.  Kelling et al. (2002) observed that 
calves inoculated with high-virulence strains developed more signs of respiratory tract 
disease, displayed elevated rectal temperature 6 days following inoculation, and 
exhibited more lethargic demeanor as compared to calves challenged with low-virulent 
strains.    
The variation in virulence exposes challenges from a research standpoint.  
Efficacy of vaccine and vaccine use protocol studies in the field have been limited by the 
lack of repeatability and under-developed accepted criteria for appropriate research 
models.  Traditionally, results from studies using BVDV type 2 have been readily 
available; however results from BVDV type 1 challenges are less common.  One such 
BVDV1 strain that has been used in vaccines as well as a popular challenge strain is 
BVDV NY-1.  Isolated from a field case in New York, calves infected with BVDV NY-
1 were reported to respond with symptoms of pyrexia, reduction in white blood cells, 
diarrhea, reduced appetite, depression, and reddening of the gums (Baker et al., 1954).  
Ridpath and Neill (2007) summarized two problems in using BVDV NY-1 when conducting 
viral challenges; one, was that clinical presentation of infection was reported as mild in 
comparison to BVDV strains R5013, R2360, and CA0401186A, and two, was the 
conflicting results in vaccine efficacy in studies using BVDV NY-1 in the treatment 
vaccine as well as the challenge virus simultaneously.   
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One of the aforementioned BVDV strains used by Ridpath and Neill (2007) that 
compared BVDV NY-1 to other field strains was used in this research as well.  Bovine 
Viral Diarrhea Virus CA0401186A was discovered from a PI calf in California that was 
one of 24 calves with brain and skeletal deformities born to heifers in a single herd.  
Tissues containing CA0401186a were submitted to the USDA-ARS National Animal 
Disease Center in Ames, IA from the Tulare Laboratory of the California Animal Health 
and Food Safety Laboratory.  It was characterized as a noncytopathic biotype and found 
to be of the BVDV1b subgenotype (Ridpath and Neill, 2007).   
Wilson (1989) defined the efficacy of a vaccine as its ability to reduce the overall 
level of respiratory disease. With this broad definition, a limited amount of literature 
exists pertaining to positive results for the efficacy of vaccination strategies in field 
trials.  Reasons for this limitation were summarized by Wilson (1989) in that the 
methods of identifying respiratory disease are often based on clinical observation only.  
Variables including severity of illness and length of illness are un-detected.  Finally, 
differences of repeatability issues which are unavailable in field studies as compared to 
laboratory evaluations (Wilson, 1989). 
Considering the complex characteristics of BVDV, there is also complexity in 
BVDV vaccination strategies. Fulton et al. (2002) observed that BVDV was an 
important contributing factor to BRD in 2 studies, with BVDV subtype 1b being the 
most predominant. Fulton et al. (2002) and Fulton et al. (2005) also briefly reviewed 
popular BRD vaccines containing BVDV, and summarized that only a small number of 
commercially available vaccines actually contained BVDV 1b antigenic material.  The 
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problem here is that even though cattle are vaccinated with BVDV 1a or 2, they may still 
be susceptible to the most common BVDV subtype, 1b.  Fulton et al. (2005) concluded 
that vaccination with a MLV vaccine containing BVDV subtypes 1a and 2 did not 
prevent infection in vaccinated calves when exposed to PI calves with BVDV1b.  Fulton 
et al. (2003a) also reported that vaccines containing BVDV1a induce lower antibodies to 
BVDV1b than to BVDV1a in 3 separate USDA licensed vaccines.   
Summary 
Bovine Respiratory Disease Complex is costly and remains widespread in beef 
cattle production systems. Morbidity and mortality result from exposure to viral and 
bacterial infections that work in concert to activate immune responses. Breed types and 
combinations of breeds have also been linked to a lower incidence of BRD. One major 
component of BRD is Bovine Viral Diarrhea Virus.  One of the reasons BVDV draws 
much attention is due to Persistently Infected (PI) calves that go unidentified as a major 
source of spreading infection. Even in events of immunization, exposure to varying 
subtypes to BVDV can still result in infection leaving questionable results of vaccine 
efficacy. Thus, research is needed that addresses the genetic influences related to health, 
immune responses and animal performance in cattle exposed to BVDV. 
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CHAPTER III 
 
EVALUATION OF WEIGHT GAIN, RECTAL TEMPERATURE AND IMMUNE 
RESPONSE OF ANGUS-SIRED STEERS CHALLENGED WITH BOVINE VIRAL 
DIARRHEA VIRUS 
Introduction 
 
Growing cattle on pasture and in feedlots can experience limited productivity 
from the presence of viral and bacterial agents that make-up a complicated disease 
system known as Bovine Respiratory Disease (BRD) complex (Gardner et al., 1999; 
Roeber et al., 2001).  During the growing and feeding phases in the beef cattle 
production, a variety of stress elements work in concert with BRD pathogens to reduce 
immune function and ultimately allow for infection and morbidity (Fulton et al., 2000).  
Genetic variation in BRD occurrence is another subject with very little reported findings. 
In those studies however, differences between breed types in susceptibility have been 
identified (Muggli-Cockett et al., 1992; Snowder et al., 2006). 
 One disease that is an important component in the BRD complex is Bovine Viral 
Diarrhea (BVD).  As a serious threat to worldwide production (Peterhans et al., 2003), 
BVD infections suppress immune function and initiate morbidity.  Furthermore, BVD is 
important from a cow-calf production standpoint because, BVD can cause abortions, 
and, cow herds are the point of origin for persistently infected (PI) cattle.  Calves born PI 
are the result of their dams becoming infected with BVD in mid gestation before the 
calf’s immune system has fully developed.  As a result, PI calves are born 
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immunotolerant to BVD infection and serve as harbors of the virus and facilitate 
constant exposure to non-PI cattle (Grooms, 2004). 
 Vaccines for BVD are commercially available as a means to manage and 
hopefully minimize occurrences of BVD infection or offset effects of viral infection.  
Efficacy of BVD vaccines have been questioned based on the genotypes and biotypes of 
virus included (Fulton et al., 2003a); for instance, BDV type 1a is typically in vaccines, 
but BDV type 1b has shown to be the most prevalent strain in the USA (Fulton et al., 
2003a; Fulton et al., 2009).  Additionally, virulence of BVDV seems to be subject of 
much variation as well in terms of symptoms associated with infection (Ridpath and  
Neill, 2007). 
 With such complicated factors that go into BRD complex from BVDV infection, 
the objective of this research was to investigate the health measures and performance 
traits of growing cattle of known genetic background that were vaccinated for BRD and 
then challenged with BVDV. 
 
Materials and Methods 
 
Animal methods were approved by the Texas A&M University Institutional 
Animal Care and Use Committee (AUP 2007-130). 
Animals.  Seventy-three Angus-sired steers of known genetic background were 
used in this trial.  Steers were born in spring of 2007 and out of half Bos indicus cows 
from the Texas A&M University McGregor Genomics project.  No prior exposure to 
viral vaccinations occurred before the trial began, and all steers were confirmed to be 
seronegative to BVD and IBR prior to trial initiation.  Cattle were confirmed to be PI- 
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free through evaluation of ear notch sample by antigen capture ELISA at the Texas 
Veterinary medical Diagnostic Laboratory (TVMDL, Amarillo, TX). 
Vaccine treatments. Steers were stratified by sire and genomics cow family 
across the vaccine treatments of Killed group (Killed, n = 33), modified-live group 
(MLV, n = 32), and non-vaccinated group (NON, n = 8). 
Steers in the MLV treatment group were administered Arsenal 4.1® (Novartis 
Animal Health US, Inc.) on day -21 as per label instructions. Steers in the Killed 
treatment group were administered Vira-shield® (Novartis Animal Health US, Inc.) on 
day -42 and a booster at day -21 as per label instructions. Eight steers (4 from killed 
group and 4 from MLV group) were not vaccinated.  Steers in the MLV group were kept 
separate from killed and NON steers for 5 days following vaccination. 
 Viral challenge.  At day 0, steers were challenged with a type 1b non-cytopathic 
BVDV strain (CA0401186a) obtained from the USDA-ARS National Animal Disease 
Center (NADC) (Ridpath and Neill, 2007).  This strain was isolated from a persistently 
infected calf and submitted to the NADC from Tulare laboratory of the California 
Animal Health and Food Safety Laboratory.  Each steer was administered 5 mL of 
inoculum (1 × 105 TCID/mL) by placing 2.5 mL in each nasal passage; the animal’s 
nose was elevated until it was visually observed that the steer had swallowed to confirm 
challenge virus was ingested. This particular strain of BVDV was chosen for this study 
because it had previously been reported to cause recognized immunological and clinical 
signs of morbidity, but without risk of extreme illness or death (Ridpath and Neill, 2007).   
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 Sample collection.  Rectal temperatures were measured via digital rectal 
thermometer on days 0, 1, 3, 9, 14, 28, and 42 following viral challenge.  Body weights 
were also recorded, with those observations made at days -42, -21, 0, 14, 28, and 42.  
Average daily gain (ADG) was calculated for three phase increments of increment 1 
(days 0 to 14), increment 2 (14 to 28), and increment 3 (28 to 42). 
 Serology. Collection of blood was conducted via jugular venipuncture into 
evacuated tubes on days -42 and -21 before the viral challenge, day 0, and days 14, 28, 
and 42 following viral challenge.  Following collection, blood serum was harvested via 
centrifuge 2 to 4 hours following collection; centrifuge settings were to spin samples for 
20 minutes at 4oC at 4000 RPM.  Serum samples were then stored at -20oC until they 
were sent to Texas Veterinary Medical Diagnostic Laboratory (TVMDL) for 
quantification of serum neutraliazing (SN) antibody immunoglobulin G (IgG) titers for 
BVD Type 1, BVD Type 2, and IBR.   
 Clinical evaluation. Clinical observations were conducted twice daily for 14 
days following challenge to assess apparent health with a score of 0 (no symptoms), or 1 
to 5 (least severe to most severe) for commonly associated symptoms of BVD/BRD 
(cough, ocular secretion, nasal secretion, depression, diarrhea, and gauntness/shrink).  
From days 15 to 42 observations were only conducted once daily. 
 Diet. Steers were on wheat pasture from days -42 to day 0.  From days 0 to 14, 
steers were fed in a set of holding pens. From days 14 to 42 steers were held in a small 
(1 hectare) pasture.  During the period following BVDV challenge, the diet consisted of 
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average quality coastal bermudagrass hay fed, ad libitum, with no additional supplement 
following challenge. 
 Statistical analysis.  Mixed model procedures of SAS (SAS Inst. Inc., Cary, NC) 
were used so that rectal temperature and antibody titers (transformed to a log base of 2) 
were analyzed as repeated measures with a model that contains vaccine treatment, day, 
sire, vaccine treatment × day, and vaccine treatment × sire, as fixed effects.  An 
autoregressive covariance structure was utilized.  Least squares means were separated 
with two-tailed t-tests following significant F-tests (P < 0.05) from the mixed model 
analyses.  Average daily gain was analyzed with a similar model that included vaccine 
treatment, day, vaccine treatment × day, pen, maternal grandsire, and vaccine treatment 
× MGS interaction and day 0 weight as a covariate.  Eight steers (n = 4 from killed 
vaccine group, n = 4 from MLV vaccine group) were removed from this analysis due to 
them not receiving viral challenge, and are not included in these results. 
 
Results and Discussion  
 A general summary of the traits evaluated is presented in Table 3.1. 
 
Table 3.1 Summary statistics for traits measured in 2008 trial 
Variable Mean SD Minimum Maximum 
IBR1 2.19 2.3 0 9.0 
BVD Type 11 3.65 3.8 0 13.0 
BVD Type 21 3.44 3.7 0 13.0 
Rectal Temperature, oC  38.8 1.58 37.44 40 
ADG, kg/day .38 .26 -.87 .89 
1
 Titer transformed to log base of 2 
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 Results of the statistical analyses are presented in Table 3.2. 
 
Table 3.2 Significance levels from mixed model analysis for health measures 
Effect IBR BVD1 BVD2 Rectal temperature 
Vaccine treatment < 0.001 < 0.001 <0 .001  0.66 
Day <0 .001 < 0.001 < 0.001  0.12 
Vaccine treatment × 
Day 
<0 .001 < 0.001 < 0.001  0.94 
Sire  0.33  0.17  0.12  0.80 
Vaccine treatment × 
Sire 
 0.54  0.06  0.09  0.98 
 
 
IBR titers.  Titers for IBR were evaluated in an attempt to evaluate vaccine 
effectiveness and pathogen exposure.  Steers in both vaccinated groups should have 
developed titers to IBR, whereas those not vaccinated should not have developed titers, 
and, this was observed.  Differences in IgG titer levels for IBR were observed due to 
vaccine treatment, day, and vaccine treatment × day interaction (P < 0.01).  Least 
squares means for the interaction are presented in Figure 3.1.   
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Figure 3.1.  Least squares means for serum neutralizing antibody titer  (log2) for IBR in 
steers of killed vaccine (Killed), modified-live vaccine (MLV), or non-vaccinated 
control (NON) groups across time in 2008 
 
 
Large differences between treatment groups were observed with steers from the 
Killed group being the highest at days 0, 14, 28, and 42 as compared to MLV and NON 
vaccinated cattle.  Titer levels within the Killed group were highest at day 0 (P < 0.01), 
followed by day 14, then 28, and, these were higher than days -42, -21, and 42 for cattle 
within the Killed group.  Titers for IBR within the Killed group at day 42 were higher 
than days -42 and -21. 
Steers in the MLV group had higher IBR titers than steers from the NON group 
at all dates measured after the viral challenge including day 0.  Differences within the 
MLV group across collection dates did vary however, with IBR titers for the MLV group 
being highest at day 0 and decreasing steadily through day 42 (P < 0.01).   After the 
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challenge on day 0, serum neutralizing IBR titers for MLV steers were lowest at days 28, 
and 42 (P < 0.01). 
BVD Type 1 titers.  Differences in BVD Type 1 titers were observed due to 
vaccine treatment, day, and vaccine treatment × day interaction (P < 0.01).  Figure 3.2 
shows the least squares means from the interaction. 
 
 
Figure 3.2 Least squares means for serum neutralizing antibody titer  (log2) for BVD 
Type 1 in steers of killed vaccine (Killed), modified-live vaccine (MLV), or non-
vaccinated control (NON) groups across time in 2008 
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On days 0 through 42 it was observed that BVD Type 2 titers from the Killed 
group were higher than the MLV or NON vaccinated group at each day.  A large 
difference in titers from day 0 to day 14 was observed (P < 0.01).  Following this peak 
BVD Type 1 titers from the Killed group remained similar through day 42.  
Calves in the MLV group displayed higher IgG titers for BVD type 1 than the 
NON group at day 14, 28, and 42.  Titers from the MLV group steadily increased from 
day 0 through 42, which was the day with the highest level observed for cattle in this 
group (P < 0.01).  
Titers for BVD Type 1 from calves within the NON group were observed to 
resemble titers from the MLV group.  Titers from the NON group increased gradually 
until their highest point was observed at day 42. 
BVD Type 2 titers.  Differences in BVD Type 2 titers were observed due to 
vaccine treatment, day, and vaccine treatment × day (P < 0.01).  Least squares means for 
the vaccine × day interaction are presented in Figure 3.3.   
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Figure 3.3.  Least squares means for serum neutralizing antibody titer  (log2) for BVD 
Type 2 in steers of killed vaccine (Killed), modified-live vaccine (MLV), or non-
vaccinated control (NON) groups across time in 2008 
 
 
 
Serum neutralizing titers for BVD Type 2 from cattle in the Killed group were 
the highest at all days measured following the viral challenge including day 0  as 
compared to cattle in the MLV and NON groups (P < 0.01).  A large increase in blood 
titers for BVD Type 2 from the Killed group was observed from day 0 to day 14.  Titer 
levels for BVD Type 2 within the Killed group peaked at day 14 (P < 0.05). Following 
this peak a slight decrease in titers were observed and titer held at this level with no 
significant changes from day 28 through 42. 
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Blood titer levels for BVD Type 2 from the MLV group steadily increased from 
day 0 through 42.  Unlike the pattern of Killed group BVD Type 2, titers in the MLV 
group peaked at days 28 and 42 (P < 0.01).  Serum titers for BVD Type 2 from cattle in 
the NON group steadily increase from day 0 to peak at day 42 (P < 0.01). 
Average daily gain.  Differences in average daily gain were also observed due to 
vaccination treatment groups.  Least squares means for ADG are shown in Table 3.3. 
 
 
Table 3.3.  Least squares means and SE for average daily gain for the three, 2-week 
periods following BVDV challenge 
 Vaccine Treatment 
 Killed MLV NON 
ADG d 0-14 (kg) 0.45a  ± .15 0.00b ± .15 -0.50b ± .29 
 
ADG d 14-28 (kg) 1.79 a ± .08 1.27 b ± .08 1.36 b ± .15 
 
ADG d 28-42 (kg) 0.27 a ± .10 0.14 a ± .11 0.14 a ± .20 
abLeast squares means with different superscripts within a row differ (P < 0.05) 
 
 
 
In 2 out of 3 two-week observation periods, the ADG for the Killed group was 
higher than MLV and NON treatment groups (P < 0.05).  Additionally, it was observed 
that cattle from the NON group lost 0.5 kg/d, which was 0.95kg/d lower than the mean 
of the Killed group (P < 0.05). 
 Summary.  Vaccine strategies are beneficial when incorporated into growing 
cattle systems.  Across the entire trial, cattle vaccinated with either an MLV or Killed 
vaccine had higher IgG titer for IBR, BVD Type 1, and BVD Type 2 than non-
vaccinated cattle.  For the first 14 d following challenge the Killed group gained 0.45 
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kg/d, the MLV group gained no weight, and the non-vaccinated steers lost 0.50 kg/d.  
All cattle gained weight in the second 14-d period, but the killed group still had an 
advantage over the MLV and NON groups.  Although steers in the killed vaccine group 
had a higher ADG than the MLV and non-vaccinated steers in the first 28 d, there was 
no obvious reason for this separation in ADG between the killed and MLV vaccinated 
groups, particularly since there were no differences in rectal temperatures.  In this trial, 
the use of vaccines sufficiently stimulated the immune system before the viral challenge 
which aided in maintaining higher ADG in vaccinated steers as compared to non-
vaccinated animals.  
No clear differences due to sire and sire × treatment were observed in any 
measurement taken.  It was unexpected that no animals had high enough rectal 
temperature (> 40.0 C) to be treated with an antimicrobial, and it appears that the 
relationship between these IgG titers and rectal temperature is not clear.  Very large 
differences in titers were observed among individuals. 
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CHAPTER IV 
EVALUATION OF FEED INTAKE, HEALTH AND IMMUNE RESPONSE IN 
ANGUS-SIRED STEERS CHALLENGED WITH 
BOVINE VIRAL DIARRHEA VIRUS 
Introduction 
 Bovine Respiratory Disease (BRD) can be an enormous burden in beef cattle 
operations.  In terms of financial strain on the U.S. cattle industry,  Griffin (1997) 
summarized an estimated annual loss of $750 million due to BRD incidence.  Galyean et 
al. (1999) calculated that 52% of U.S. feedlot morbidity was a result of BRD.  Morbidity 
from BRD is most common in the first 45 days after arrival, as during this time cattle are 
subjected to and recovering from added levels of stress which requires additional 
management (Edwards, 2010).  Illness from BRD often results in reduced appetite along 
with other signs of disease. Buhman et al. (2000) observed reduced intake behavior and 
lower frequency of intake in newly arrived feedlot cattle identified as sick as compared 
to non-sick contemporaries. 
 Morbidity due to BRD comes from pathogenic bacteria, typically following the 
presence of one of more viral infections (Daniels et al., 2000). The viral components of 
BRD create suppressed immune function and leads to infectious bacterial pneumonia, 
most commonly caused my Mannheimia haemolytica (Fulton et al., 2000; Fulton et al., 
2002; Fulton et al., 2006). Differences among breed types have also accounted for BRD 
occurrences. Muggli-Cockett et al. (1992) reported Angus cattle had the lowest 
percentage of occurrence compared to several other breeds. 
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 Bovine Viral Diarrhea Virus is a component of BRD which is a subject of great 
interest due to the production nuisances BVD creates in cow herds which carries over 
into the growing and finishing phases of beef production (Larson et al., 2002).  Vaccines 
containing BVDV antigenic material are available and contain modified-live or killed 
forms of viral agents which initiate cattle immune systems (Faries, 1999).  The efficacy 
of vaccines tends to be difficult to measure in field studies, mainly from the lack of 
standardized methods for detecting clinical illness and illness severity. 
Due to the amount of variation in results that involve vaccine efficacy combined 
with the lack of reported information pertaining to the genetic influence in respiratory 
illness, the objective of this research was to investigate the immune response, feed 
intake, growth performance, and genetic variability of steers with known genetic 
background when challenge with BVDV following different vaccination strategies. 
 
Materials and Methods 
Animal methods were approved by the Texas A&M University Institutional 
Animal Care and Use Committee (AUP 2007-130).  
Animals.  Ninety-three Angus-sired, yearlings steers produced from the Texas 
A&M University McGregor Genomics Project cows, born in the spring of 2008 were 
used to conduct this trial.  No prior exposure to viral vaccinations occurred before the 
trial began and all steers were confirmed to be seronegative to BVD and IBR prior to 
trial initiation.  Cattle were confirmed to be PI free through evaluation of ear notch 
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sample by antigen capture ELISA at the Texas Veterinary medical Diagnostic 
Laboratory (TVMDL, Amarillo, TX). 
 Vaccine treatments. Steers were stratified by sire and genomics cow family 
across 3 vaccine treatment groups; killed vaccine (Killed) group (n = 29), modified-live 
(MLV) group (n = 34), and non vaccinated (NON) group (n = 31). 
 Steers in the Killed group received initial Vira-shield® (Novartis Animal Health 
US, Inc.) vaccine on day -56 and a booster dose on day -35 as per label instruction. 
Steers in the MLV group were vaccinated with Arsenal 4.1® (Novartis Animal Health 
US, Inc.) on day -35 prior to the challenge and remaining 31 steers of the NON group 
remained as non-vaccinated.  Steers receiving the MLV were kept separate from Killed 
and NON steers for 7 days following vaccination.  These were the same vaccines used in 
the 2008 trial. 
 Viral challenge.  At day 0, steers were challenged with a type 1b non-cytopathic 
BVDV strain (CA0401186a) obtained from the USDA-ARS National Animal Disease 
Center (Ridpath and Neill, 2007).  This strain was isolated from a persistently infected calf 
and submitted to the NADC from Tulare laboratory of the California Animal Health and 
Food Safety Laboratory.  Each steer was administered 5 mL of inoculum (1 × 105 
TCID/mL) by placing 2.5 mL in each nasal passage; the animal’s nose was elevated until 
it was visually observed that the steer had swallowed to confirm challenge virus was 
ingested. This particular strain of BVDV was chosen for this study because it had 
previously been reported to cause recognized immunological and clinical signs of 
morbidity, but without risk of extreme illness or death (Ridpath and Neill, 2007).  This was 
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the same BVDV strain and challenge technique used as in the previous year’s (2008) 
trial. 
 Sample collection.  Body weights were measured and rectal temperatures were 
evaluated via digital rectal thermometer on days 0, 1, 3, 7, 10, 14, 28, and 42 following 
viral challenge.  Average daily gain (ADG) was calculated for three periods: period 1 
(days 0 to 14), period 2 (days 14 to 28), and period 3 (days 28 to 42). 
Serology. Collection of blood was conducted via jugular venipuncture into 
evacuated tubes on days -56 and -35 before the viral challenge, days 0, 14, 28, and 42 
following viral challenge.  Following collection, blood serum was harvested via 
centrifuge 2 to 4 hours following collection, centrifuge settings were to spin samples for 
20 minutes at 4oC at 4000 RPM.  Serum samples were then stored at -20oC until they 
were sent to Texas Veterinary Medical Diagnostic Laboratory (TVMDL) for 
quantification of serum neutraliazing (SN) antibody immunoglobulin G (IgG) titers for 
BVD Type 1, BVD Type 2, and IBR. 
Clinical evaluation. Clinical observations were conducted twice daily for 14 
days following challenge to assess apparent health with a score of 0 (no symptoms), or 1 
to 5 (least severe to  most severe) for commonly associated symptoms of BVD/BRD 
(cough, ocular secretion, nasal secretion, depression, diarrhea, and gauntness/shrink).  
From days 15 to 42 observations were only conducted once daily.  Animals exhibiting 
rectal temperatures over 40oC were administered a commercially available antimicrobial 
approved for cattle and dosed per label directions.  
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Diet and feed intake monitoring. Cattle were fed a high-forage growing diet 
that consisted of 35.5% corn, 32.5% chopped alfalfa hay, 24.5% dry distillers grains, 
2.5% commercial premix, and 5% molasses. Cattle were housed and fed at the Texas 
A&M University Beef Systems Research Unit on FM 50 where 4 pens are equipped with 
GrowSafe® feed intake observation units. Cattle were housed so that the treatment 
groups were stratified across the 4 pens with approximately 23 steers per pen.  
Statistical analysis.  Mixed model procedures of SAS (SAS Inst. Inc., Cary, NC) 
were used so that rectal temperature and titer level (transformed to a log-base of 2) were 
analyzed as repeated measures with vaccine treatment, day, vaccine treatment × day, sire 
or family, and vaccine treatment × sire evaluated as fixed effects. An autoregressive 
covariance structure was utilized.    Average daily gain and feed intake were analyzed 
with similar model that included vaccine treatment, day, vaccine treatment × day 
interaction, pen, maternal grandsire and vaccine treatment × maternal grandsire 
interaction.  Least squares means were compared for effects that produced a significant 
F-test (P < 0.05). 
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Results and Discussion 
 General summary statistics for traits evaluated are provided in Table 4.1. 
                      
Table 4.1 Summary statistics for traits studied in 2009 trial 
 1Titer transformed to log base of 2 
 
 
 
 Results from statistical analyses are provided in Table 4.2. 
 
Table 4.2 Significance levels from mixed model analysis for IBR, BVD Type 1, BVD     
Type 2, and rectal temperature 
Effect IBR BVD Type 1 BVD Type 2 Rectal Temperature 
Vaccine treatment < 0.001 < 0.001 < 0.001 < 0.05 
Day < 0.001 < 0.001 < 0.001 < 0.001 
Vaccine ×day < 0.001 < 0.001 < 0.001 < 0.05 
Sire 0.71 0.06 0.20 < 0.05 
Vaccine × sire  0.81 0.14 0.60 0.64 
 
 
 
IBR titers.  Titers for IBR were evaluated as a control variable as cattle that 
were vaccinated for BRD should be the only animals with IBR titers.  Vaccine treatment, 
day, and vaccine treatment × day interaction affected IBR titers (P < 0.01).  Figure 4.1 
shows titers for IBR across vaccine groups and sample dates. 
 
Variable  Mean SD Minimum Maximum 
IBR1 1.61 2.13 0 7.0 
BVD Type 11 3.51 3.69 0 13.0 
BVD Type 21 3.08 3.55 0 14.04 
Rectal temperature,  oC 39.29 .54 37.2 41.30 
ADG, kg 1.7 .38 .7 2.8 
Daily intake, kg 12.18 3.58 0 24.6 
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Figure 4.1.  Least squares means for serum neutralizing antibody titer response (log2) of  
IBR across days in steers of killed vaccine (Killed), modified-live vaccine (MLV), or  
non-vaccinated control (NON) groups in 2009 
 
 
 
Large titer differences for cattle in the Killed group were observed at days -35, 0, 
14, 28, and 42 as compared to MLV and non-vaccinated (NON) (P < 0.01). The highest 
IBR titers for the Killed group were observed at day 0 compared to days -56, -35, 14, 28, 
42 (P < 0.01).  IBR titers in the Killed group at day 14 were also higher than days -56, -
35, 28, and 42 (P < 0.01).  IBR titers for the Killed group at days 28 and 42 were not 
different from each other (P = 0.86), but were higher than days -56 and -35 (P < 0.01). 
Titer differences for IBR in the MLV group were higher than the NON group at 
days 0, 14, 28, 42 (P < 0.01) but differences in IBR titers for the MLV group for days 0, 
14, 28, 42 were not different from each other (P > 0.10). 
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BVD Type 1 titers.  Vaccine treatment, day, and vaccine treatment by day 
interaction affected BVD Type 1 titers (P < 0.01).  Figure 4.2 shows least squares means 
for BVD Type 1 titers across vaccine group and sample date combinations. 
 
 
 
Figure 4.2.  Least squares means for serum neutralizing antibody titer response (log2) of  
BVD Type 1 across days in steers of killed vaccine (Killed), modified-live vaccine  
(MLV), or non-vaccinated control (NON) groups in 2009 
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Titers for BVD Type 1 in the Killed group were higher than MLV and NON 
groups at days 14, 28, and 42 (P < 0.01).  Differences between days within the same 
vaccine group were also observed.  Titers in the Killed group were highest at days 14 
and 28.  Titers for BVD Type 1 in the Killed group at day 14 were higher than days -56, 
-35, 0, and 42 (P < 0.01) and titers at day 28 were higher than -56, -35, and 0, but were 
not significantly different from day 14 or day 28 (P = 0.16, P = 0.08 respectively). Titers 
in the Killed group at day 0 were higher than -56 and -35 (P < 0.01), but not days 14, 28, 
and 42. 
Titers for BVD Type 1 in the MLV group were higher than titers from the NON 
vaccine group at days 0, 14, 28, 42 (P < 0.01).  Titers from the MLV group were 
observed to be similar to Titers from the Killed group at day 0 but were not significantly 
different (P = 0.13).  Titers for BVD Type 1 in the MLV group were highest at day 42 as 
compared to any other day (P < 0.05). 
Titers for BVD Type 1 in the NON group progressively increased over time with 
the highest recorded titers being observed at day 42 (P < 0.01). 
BVD Type 2 titers.  Figure 4.3 shows least squares means for BVD Type 2 titers 
across vaccine group and sample dates observed. 
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Figure 4.3.  Least squares means for serum neutralizing antibody titer response (log2) of  
BVD Type 2 across days in steers of killed vaccine (Killed), modified-live vaccine  
(MLV), or non-vaccinated control (NON) groups in 2009 
 
 
 
Titers for BVD Type 2 in the Killed group were higher than titers from the MLV 
and NON treatment groups at all dates from day 0 through day 42 (P < 0.01).  Killed 
group titers were highest at day 14, which was significant as compared to other dates 
within that treatment group (P < 0.01).  Titers in the Killed group for BVD Type 2 on 
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days 28 and 42 were not significantly different (P = 0.06), but were still substantially 
higher than days 0, -56, -35 in the Killed group (P < 0.01). 
Titers for BVD Type 2 in the MLV group were higher than the NON group at 
days 0, 14, 28 (P < 0.01), but were not significantly different the NON group at day 42 
(P = 0.87).  Titers for BVD Type 2 in the MLV group were highest at days 28 and 42.  
Similar to BVD Type 1, BVD Type 2 titers from cattle in the NON group progressively 
increased over time and were highest at day 42. 
Pen assignment was not a significant source of variation for titer response for 
IBR, BVD Type 1, or BVD Type 2 (P = 0.34, 0.63, and 0.56, respectively). 
Rectal temperature.  Differences in rectal temperature were observed due to 
vaccine treatment, day, vaccine treatment by × day interaction, and sire.  Figure 4.4 
shows differences in rectal temperatures.  Peak least squares means for rectal 
temperature response occurred at day 7.  Steers from the MLV group remained lower 
(39.2oC) for rectal temperatures than steers in the Killed group and NON group (P < 
0.05), which were highest at 39.8oC and 39.8oC, respectively on day 7. 
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Figure 4.4.  Least squares means for rectal temperature (oC) over time of steers in killed  
vaccine (Killed), modified-live vaccine (MLV), or non-vaccinated (NON) groups  
following BVDV challenge on day 0 
 
 
 
Following day 7, rectal temperatures dropped below 39.0oC for all vaccine 
groups then steadily rose through day 28 when it was observed that temperatures for 
cattle in the Killed group reached a secondary peak which was significantly higher than 
all measured rectal temperatures within the killed group days except day7 (P < 0.05).  A 
similar pattern was observed for the NON cattle as their temperatures appeared to peak 
again at day 28 as compared to other measured dates, excluding days 3 and 7 (P ≤ 0.05).   
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 Antimicrobial treatment was assessed when observed rectal temperatures were  
 
greater than 40oC.  A summary of the number of cattle treated across vaccine treatment  
 
group are presented in Table 4.3. 
 
 
 
Table 4.3. Number of cattle treated (rectal temperature > 40oC) days 0 to 14 across 
vaccine groups 
 
 
 
 
Yes – rectal temperature > 40oC 
No – rectal temperature ≤ 40oC 
 
 
Following viral challenge and ensuing effects of inflammation, the observed 
rectal temperatures at day 42 across all three returned to within 0.1oC of each other at 
39.3oC, 39.2oC, and 39.2oC for Killed, MLV, and NON groups, respectively.  
Differences in rectal temperature due to sire were also observed, and means are 
presented in Table 4.4.  
 
Table 4.4.  Least squares means and standard  
errors for rectal temperature for sire groups  
across all days 
 
abcdeLeast squares means with different  
subscripts are different (P < 0.05).  
 Killed MLV NON TOTAL 
NO 14 34 17 65 
YES 14 0 14 28 
Sire Rectal Temperature  SE 
006Na 39.28oC ± 0.05   
012Rab 39.34oC ± 0.07   
023Nbc 39.45oC ± 0.06 
032Nabc 39.33oC ± 0.12 
178Nad 39.15oC ± 0.09 
215Rde 39.07oC ± 0.11 
252Pde 39.12oC ± 0.07 
548Pabc 39.36oC ± 0.04 
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Calves sired by 252P and 215R displayed the lowest overall least squares mean 
temperature (39.12oC and 39.12oC, respectively) for all days collected as compared to 
calves sired by 548P, 032N, 023N, 012R, and 006N regardless of vaccine treatment 
group (P < 0.05). 
Feed intake.  Differences in daily feed intake were observed due to vaccine 
treatment, day, and vaccine treatment × day. Figure 4.5 shows least squares means for 
daily intake across vaccine groups.  Steers from the MLV group consumed more than 
steers in the Killed group and the NON group.  The largest variation in differences 
between the vaccine groups appeared to occur from days 7 to 10 following the BDVD 
challenge where NON steers consumed 0.59 to 4.92 kg/day less that MLV and Killed 
groups.  Figure 4.6 shows least squares means for daily intake across vaccine groups for 
the first 14 days following viral challenge, including the separation of cattle that were 
treated and not treated within those vaccine groups based on rectal temperature 
(>40.0oC).  These results are similar to (Buhman et al., 2000) in that cattle that are 
treated displayed a reduction in appetite.    
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Figure 4.5.  Least squares means for daily feed intake (kg) for the vaccine treatment by 
day interaction (P < 0.05) 
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Figure 4.6.  Least squares means for daily feed intake of steers in the 14 days following 
BVDV challenge due to combinations of vaccine treatment group and whether or not 
they were treated (based on rectal temperature > 40.0 C) 
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Differences in daily feed intake were observed due to maternal grand sire (MGS) 
and MGS × vaccine treatment interaction (least squares means are presented in Table 
4.5) 
 
Table 4.5.  Least squares means for overall daily feed intake for  
vaccine treatment by maternal-grandsire (MGS) interaction 
 Vaccine treatment 
 
MGS 
 
Killed ± SE 
 
MLV ± SE 
 
NON ± SE 
 
297J 13.2ax ± 0.23 12.9ax ± 0.23 12.3ay ± 0.25 
432H 11.9bx ± 0.19 12.4ay ± 0.18 11.8abx ± 0.19 
437J 11.9bcx ± 0.25 12.9ay ± 0.21 12.5acy ± 0.21 
551G 11.2cdx ± 0.25 11.6bx ± 0.23 11.4bx ± 0.25 
abcLS means with different superscripts within maternal grandsire  
column are different (P < 0.05) 
xyLS means with different superscripts within vaccine treatment row  
are different (P < 0.05) 
 
 
 
Steers in the Killed group from MGS 297J consumed more than steers from 
MGS 432H, 437J, and 551G (P < 0.05).  When comparing grand-progeny of 297J across 
vaccine treatments, cattle in the NON group consumed 0.9 kg/day less than those in the 
Killed group and 0.6 kg/day less than those in the MLV group (P < 0.05).  Similar 
patterns of differences across vaccine treatments within a MGS group were observed for 
steers with 432H in their pedigree.  Steers from 432H in the MLV group consumed 0.5 
kg/day and 0.6 kg/day more than steers from the Killed group or the NON group, 
respectively (P < 0.05).  Steers from MGS 437J consumed 1 kg/day and .6 kg/day less as 
part of Killed group as compared to steers from 437J in the MLV and NON groups, 
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respectively.  Calves from MGS 551G, regardless of vaccine group, consumed the least 
in all cases (P < 0.05). 
Average daily gain.  Calculations of ADG were conducted but no differences 
existed in any 14-day period, which is similar to observations made by Wittum et al, 
(1996) in that no differences in ADG were observed due to treatment or vaccine status. 
 Summary.  Similar to results in the 2008 trial, vaccinated cattle responded with 
higher titers for IBR, BVD Type 1 and BVD Type 2 as compared to non-vaccinated 
cattle following the viral challenge.  Differences in rectal temperature were also 
observed due to sire.  Cattle in the MLV treatment group remained lower following viral 
challenge, and as a result no cattle in the MLV group were treated in the first 14 days 
post challenge.  Additionally, all steers in the MLV group and fourteen steers in the 
Killed vaccine group that were not treated maintained an increasing daily intake days 6 
through 9 post challenge when all cattle in the NON vaccine group and fourteen steers in 
the Killed vaccine group that were treated exhibited a sharp decrease in daily feed 
consumption.  Differences in daily feed intake were observed due to MGS and MGS × 
treatment interaction.  Preliminary analysis for ADG and daily feed intake included sire, 
but it was not a significant source of variation. MGS was then investigated and 
accounted for differences and was therefore left in the analysis.  These interactions that 
exist between sires and treatments as well as MGS and treatments provide evidence that 
genetics along with vaccine strategy management plays a significant role in the 
differences of animal health response to BVDV infection.  The role of genetic 
background on vaccination response to BVD has not been reported in the literature.  
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Genetic background has been shown to influence BRD incidence (Muggli-Cockett et al., 
1992; Snowder et al., 2006).  If future studies find genetic background influences BVDV 
immune response then this information would need to be documented for improved 
BVD control strategies and could impact producers’ animal selection and vaccine 
choices, and even veterinarian recommendations.  
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CHAPTER V 
SUMMARY 
 This chapter is included to compare and contrast the results of the 2008 and 2009 
trials.  While these trials were very similar in the objectives and sources of animals and 
methodology, substantial differences between the trials were evident.  
 The summary statistic Tables 3.1 and 4.1 present some differences; the most 
obvious are the results for ADG between the 2 years. The mean for the 2008 trial was 
.38 kg/day as compared to the 2009 trial where the mean was 1.7 kg/day.  This 
difference can be accounted for by the types of diets each set of steers was fed during the 
observation period; steers in 2008 were fed average quality bermudagrass hay whereas 
steers in 2009 were fed a mixed growing ration.  Rectal temperature differences were 
also evident in terms of the maximum temperatures recorded.  In the 2008 study a 
maximum value of 40.0oC was observed and no animals were treated with an 
antimicrobial, whereas in 2009 the maximum temperature achieved was 41.3oC, and 
there were 35 of 93 (37%) treated with an antimicrobial.  In both trials the source of 
cattle, vaccines administered, and virus exposure were similar, so no clear explanation 
exists for this difference in rectal temperature response between years.  It is important to 
note that the diets, timing between vaccination and viral challenge, along with weather 
conditions between each trial were different, thus further investigation is needed to 
determine the effects these differences have on vaccine response in growing steers.  
 Serum IgG titer for IBR for cattle in the 2008 trial and 2009 trial were very 
similar for the killed vaccine group being the highest at day 0 and descending through 
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day 42.  Cattle in the MLV vaccine group between the 2 years was less similar however, 
as the IBR titer from the 2009 trial seemed to remain at a constant level unlike the 
descending pattern observed in the 2008 trial for IBR titer.   
 Serum IgG titer for BVD Type 1 was very similar between the 2 years after day 
0.  Titer levels for BVD Type 1 from the Killed group was higher than the MLV and 
non-vaccinated groups except at day 0 of the 2009 trial where no differences existed 
between the MLV and Killed groups.  In each trial, the non-vaccinated group displayed 
an ascending pattern with most of the increase occurring from day 14 to day 28.  Less of 
an increase occurred from day 28 to 42 in both years.  In both trials the only exposure to 
BVDV occurred at d 0 and since the vaccinated cattle were immunized, their titer 
response was higher and more rapid as compared to the non vaccinated steers.     
 Serum IgG titer for BVD type 2 in the Killed vaccine group was similar between 
the 2 years. In both years a large increase from day 0 to day 14 occurred and titer levels 
for the Killed vaccine group descended from day 14 to day 42.  The MLV vaccine group 
between the 2 years displayed less similar patterns at day 0 where MLV group titer level 
for BVD type 2 was not different than the NON vaccine group in 2008 but was 
significantly different in 2009.  Titer levels for the MLV group between the 2 trials were 
reflective in the ascending pattern through day 42.  This similar ascending pattern was 
also observed in non-vaccinated steers. 
 Differences in the source of variation can also be observed in measurements that 
were taken in both trials.  Sire accounted for more of the difference in rectal temperature 
in the 2009 trial as compared to the 2008 trial, and some of this difference may have 
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been due to the improved balance of sires across treatments in 2009.  Vaccine treatment 
was a large source of variation for ADG in the 2008 trial but not in the 2009 trial, this 
may be due to an improved plane of nutrition for the 2009 trial since a complete mixed 
ration was fed.   
 Overall, this study shows that the relationships among health and performance 
traits are complex when cattle are exposed to BVD virus.  The reduction of feed intake 
among the non-vaccinated cattle that showed no apparent increase in rectal temperature 
needs more research.  There appears to be substantial genetic variation to select for IgG 
titers in response to BVDV, but whether or not this is the best genetic strategy to follow 
needs further investigation.  
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